β1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5374-5382

  Goel, Hira Lal ^a   Moro, Loredana ^a,d   Murphy Ullrich, Joanne E ^b   Hsieh, Chung Cheng ^a   Wu, Chin Lee ^c   Jiang, Zhong ^a   Languino, Lucia R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b University of Alabama at Birmingham   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; BETA INTEGRIN 1A; BETA INTEGRIN 1C; SMALL INTERFERING RNA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; BETA1 INTEGRIN; SCLEROPROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; PROTEIN VARIANT; UPREGULATION; ANIMAL; CELL DIVISION; CYTOLOGY; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; PROSTATE TUMOR; TRANSGENIC MOUSE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD29; APOPTOSIS; CELL DIVISION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; THROMBOSPONDIN 1; TRANSFECTION; UMBILICAL VEINS;

EID: 67650466367     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0186     Document Type: Article

References (54)

1. Culig Z, Bartsch G. Androgen axis in prostate cancer. J Cell Biochem 2006;99:373-81.
2. De Marzo AM, DeWeese TL, Platz EA, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91:459-77.
3. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006;27:1-22.
4. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001;20:321-31.
5. 3 in prostate cancer progression. Neoplasia 2002;4:191-4.
6. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;3:657-64.
7. Knudsen BS, Miranti CK. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 2006;99:345-61.
8. Alam N, Goel HL, Zarif MJ, et al. The integrin-growth factor receptor duet. J Cell Physiol 2007;213:649-53.
9. 1C integrin in prostatic adenocarcinoma. J Clin Invest 1999;103:321-9.
10. 1 integrin variants in human prostate carcinoma. Am J Pathol 2000;157:1727-34.
11. 1 integrins. J Cell Biol 2004;166:407-18.
12. Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 2008;103:691-708.
13. Rege TA, Fears CY, Gladson CL. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol 2005;7:106-21.
14. Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004;91:125-50.
15. Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 2002;99:1527-31.
16. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-7.
17. Elzie CA, Murphy-Ullrich JE. The N-terminus of thrombospondin: the domain stands apart. Int J Biochem Cell Biol 2004;36:1090-101.
18. Rege TA, Stewart J, Jr., Dranka B, Benveniste EN, Silverstein RL, Gladson CL. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009;218:94-103.
19. Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008;22:3968-79.
20. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
21. Vallbo C, Wang W, Damber JE. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 2004;93:1339-43.
22. Colombel M, Filleur S, Fournier P, et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 2005;65:300-8.
23. Jin RJ, Kwak C, Lee SG, et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000;7:1537-42.
24. Murphy-Ullrich JE, Gurusiddappa S, Frazier WA, Hook M. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J Biol Chem 1993;268:26784-9.
25. Annis DS, Murphy-Ullrich JE, Mosher DF. Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 2006;4:459-68.
26. Engvall E, Davis GE, Dickerson K, Ruoslahti E, Varon S, Manthorpe M. Mapping of domains in human laminin using monoclonal antibodies: localization of the neurite-promoting site. J Cell Biol 1986;103:2457-65.
27. 1 integrins. Exp Mol Pathol 2001;70:239-47.
28. Fornaro M, Plescia J, Chheang S, et al. Fibronectin protects prostate cancer cells from tumor necrosis factor α-induced apoptosis via the AKT/survivin pathway. J Biol Chem 2003;278:50402-11.
29. 1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br J Cancer 2005;92:102-12.
30. 1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Cancer Res 2006;66:331-42.
31. Altieri DC, Duperray A, Plescia J, Thornton GB, Languino LR. Structural recognition of a novel fibrinogen gamma chain sequence (117-133) by ICAM-1 mediates leukocyte-endothelium interaction. J Biol Chem 1995;270:696-9.
32. 3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003;161:817-26.
33. 1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008;68:4398-405.
34. 1A integrin cytoplasmic variants in modulating focal adhesion kinase, protein kinase B/AKT, and Ras/mitogen- activated protein kinase pathways. Mol Biol Cell 2000;11:2235-49.
35. 1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 2005;65:6692-700.
36. Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer 2003;89:2122-32.
37. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
38. 6-integrins in the normal and neoplastic prostate. Am J Pathol 1994;145:167-74.
39. 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am J Pathol 1996;149:765-73.
40. 1 integrins in teratoma interferes with basement membrane assembly and laminin-1 expression. Exp Cell Res 1998;238:70-81.
41. 1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol 1997;139:265-78.
42. Hibino S, Shibuya M, Engbring JA, Mochizuki M, Nomizu M, Kleinman HK. Identification of an active site on the laminin α5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res 2004;64:4810-6.
43. Dejong V, Degeorges A, Filleur S, et al. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene 1999;18:3143-51.
44. Mettouchi A, Cabon F, Montreau N, et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 1994;13:5668-78.
45. 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-59.
46. 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-70.
47. Schwartz MA, Assoian RK. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci 2001;114:2553-60.
48. Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P. VEGF, a prosurvival factor, acts in concert with TGF-β1 to induce endothelial cell apoptosis. Proc Natl Acad Sci U S A 2006;103:17260-5.
49. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53stat us in prostate cancer and benign prostatic hyperplasia. BJU Int 2002;89:303-9.
50. Lewis JM, Truong TN, Schwartz MA. Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci U S A 2002;99:3627-32.
51. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
52. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
53. Lee JW, Juliano R. Mitogenic signal transduction by integrin- and growth factor receptor-mediated pathways. Mol Cells 2004;17:188-202.
54. 1C inhibits prostate epithelial cell proliferation. Am J Pathol 1998;153:1079-87.